Prosecution Insights
Last updated: April 19, 2026

Examiner: KIRWIN, STEFANIE JOHANNA

Tech Center 1600 • Art Units: 1677

This examiner grants 11% of resolved cases

Performance Statistics

11.4%
Allow Rate
-48.6% vs TC avg
65
Total Applications
+28.6%
Interview Lift
1367
Avg Prosecution Days
Based on 35 resolved cases, 2023–2026

Rejection Statute Breakdown

11.2%
§101 Eligibility
11.4%
§102 Novelty
43.8%
§103 Obviousness
29.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19102345 METHOD FOR FIXING PRIMARY ANTIBODIES TO A BIOLOGICAL SAMPLE Non-Final OA PIXELGEN TECHNOLOGIES AB
17429745 SELECTION AND BLOCKADE OF FERTILIZATION COMPETENT MALE AND FEMALE GAMETES Non-Final OA University of Virginia Patent Foundation
16838623 METHOD FOR EVALUATION OF TARGET IN HISTOLOGICAL SAMPLE Non-Final OA Agilent Technologies, Inc.
17479326 METHODS AND ASSAYS FOR IMMUNE PHENOTYPING Non-Final OA University of Florida Research Foundation, Incorporated
17386733 BIOMARKERS FOR CONGENITAL VASCULAR MALFORMATIONS Non-Final OA University of South Carolina
17393866 SWCNT-DNA-ANTIBODY CONJUGATES, RELATED COMPOSITIONS, AND SYSTEMS, METHODS AND DEVICES FOR THEIR USE Non-Final OA MEMORIAL SLOAN KETTERING CANCER CENTER
18114229 DROPLET ORGANOID-BASED IMMUNO-ONCOLOGY ASSAYS AND METHODS OF USING SAME Non-Final OA Xilis, Inc.
17220888 RAPID MULTIPLEXED SEROLOGICAL TEST Final Rejection Genalyte, Inc.
17160661 BIOMARKER, METHODS, AND COMPOSITIONS THEREOF FOR EVALUATION OR MANAGEMENT OF KIDNEY FUNCTION OR DIAGNOSING OR AID IN DIAGNOSING KIDNEY DYSFUNCTION OR KIDNEY DISEASE Non-Final OA SEQUELA, INC.
17263449 BACTERIAL VAGINOSIS DIAGNOSTIC Final Rejection MOLOGIC LTD
17049004 COMPOSITIONS AND METHODS FOR EVALUATING POTENCY OF LISTERIA-BASED IMMUNOTHERAPEUTICS Non-Final OA ADVAXIS, INC.
17044199 METHOD FOR THE DIAGNOSIS OF AMYLOID-ASSOCIATED DISEASES Non-Final OA AmyloiDia Sweden AB
16572364 NOVEL PREGNANCY DIAGNOSIS DEVICE INCLUDING BETA-CORE FRAGMENT HCG AS MARKER Final Rejection ADTECH CO., LTD.
16326369 LATERAL FLOW ASSAY FOR ASSESSING RECOMBINANT PROTEIN EXPRESSION OR REPORTER GENE EXPRESSION Final Rejection Qoolabs, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month